DOCSLIB.ORG

Product List 2019 Finished Dosage Forms (Partner Label), Active Pharmaceutical Ingredients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product List 2019 Finished Dosage Forms (Partner Label), Active Pharmaceutical Ingredients Product List 2019 Finished Dosage Forms (Partner Label), Active Pharmaceutical Ingredients B2B DISCLAIMER Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. The availability of some of the listed products may be limited by geographical territory. All products are intended only to Sandoz B2B. 2 Finished Dosage Forms (Partner Label) Anti-Infectives LATIN ORAL EUROPE AMERICA APMA Aciclovir • • Amoxicillin Trihydrate • • • Amoxicillin Trihydrate + Potassium Clavulanate • • • Azithromycin Dihydrate • • Azithromycin Monohydrate • Cefadroxil • Cefalexin • • Cefuroxime Axetil • • Ciprofloxacin Hydrochloride • • Clarithromycin • • Doxycycline • Efavirenz • Efavirenz + Emtricitabine + Tenofovir Disoproxil (Succinate) • Entecavir • Lamivudine + Zidovudine • • Levofloxacin • Linezolid • Moxifloxacin Hydrochloride • • Norfloxacin • Penicillin V Potassium • • Rifampicin + Isoniazid • Rifampicin + Isoniazid + Pyrazinamide • Roxithromycin • Valganciclovir Hydrochloride • Voriconazole • • STERILE Aciclovir • Amoxicillin Sodium + Potassium Clavulanate • Cefazolin Sodium • Cefepime Hydrochloride • Cefotaxime Sodium • • Ceftazidime • Ceftriaxone Sodium • • Cefuroxime Sodium • Penicillin G Benzathine • Piperacillin Sodium + Tazobactam Sodium • • Vancomycin Hydrochloride • • Voriconazole • The availability of some of the listed products may be limited by geographical territory. 3 Blood LATIN ORAL EUROPE AMERICA APMA Acetylsalicylic Acid • Anagrelide Hydrochloride • Cilostazol • Clopidogrel Hydrochloride • Clopidogrel Hydrogensulphate • STERILE Doxorubicin Hydrochloride • Cardiology LATIN ORAL EUROPE AMERICA APMA Acetylsalicylic Acid + Atorvastatin Calcium + Ramipril • • Amiodarone Hydrochloride • Amlodipine Besylate • • Amlodipine Besylate + Atorvastatin Calcium • Amlodipine Maleate • Atenolol • • Atenolol + Nifedipine • Atorvastatin Calcium • • • Bisoprolol Fumarate • Bisoprolol Fumarate + Acetylsalicylic Acid • Captopril • Carvedilol • Doxazosin Mesylate • • Enalapril Maleate • Ezetimibe • • Ezetimibe + Rosuvastatin Calcium • Ezetimibe + Simvastatin • Hydrochlorothiazide • • Ivabradine Oxalate • Lisinopril • Manidipine Dihydrochloride • Nebivolol Hydrochloride • Perindopril Erbumine + Amlodipine Besylate • Perindopril Erbumine + Indapamide • Pitavastatin Calcium • Pravastatin Sodium • 4 The availability of some of the listed products may be limited by geographical territory. LATIN ORAL EUROPE AMERICA APMA Ramipril • • Ramipril + Amlodipine Besylate • Ramipril + Amlodipine Besylate + Hydrochlorothiazide • Ramipril + Hydrochlorothiazide • Rosuvastatin Calcium • • • Simvastatin • • • Sotalol Hydrochloride • STERILE Amiodarone Hydrochloride • Central Nervous System LATIN ORAL EUROPE AMERICA APMA Amitriptyline Hydrochloride • Aripiprazole • • Atomoxetine Hydrochloride • Bromazepam • Buprenorphine Hydrochloride + Naloxone Hydrochloride • Citalopram Hydrobromide • Donepezil Hydrochloride • Duloxetine Hydrochloride • • Escitalopram Oxalate • • Fluoxetine Hydrochloride • • Gabapentin • Hydroxyzine Hydrochloride • Lamotrigine • Levetiracetam • • Levodopa + Carbidopa + Entacapone • Levomethadone Hydrochloride • Lorazepam • Memantine Hydrochloride • Mirtazapine • Olanzapine • • Oxcarbazepine • Paroxetine Hydrochloride • • • Piracetam • Pramipexole Dihydrochloride Monohydrate • Pregabalin • • • Quetiapine Fumarate • • The availability of some of the listed products may be limited by geographical territory. 5 LATIN ORAL EUROPE AMERICA APMA Rasagiline Tartrate • Riluzole • Risperidone • Rivastigmin Hydrogen Tartrate • Ropinirole Hydrochloride • Sertraline Hydrochloride • • Topiramate • • Valeriana Officinalis • Venlafaxine Hydrochloride • • • Zolpidem Tartrate • PATCH Rivastigmin • Cough/Cold LATIN ORAL EUROPE AMERICA APMA Acetylcysteine • Acetylsalicylic Acid + Pseudoephedrine Hydrochloride • Cetirizine Dihydrochloride • Chlorhexidine Hydrochloride + Lidocaine Hydrochloride • Ebastine • Fexofenadine Hydrochloride • Oxolamine Citrate • Paracetamol + Dextromethorphan + Chlorpheniramine Maleate + • Phenylephrine Hydrochlorid Paracetamol + Dextromethorphan + Pseudoephedrine Hydrochloride • Paracetamol + Phenylephrine Hydrochloride • Dermatological LATIN DERMATOLOGICAL EUROPE AMERICA APMA Aciclovir • Ketoconazole • Mometasone Furoate • Naftifine Hydrochloride • • 6 The availability of some of the listed products may be limited by geographical territory. Diabetes LATIN ORAL EUROPE AMERICA APMA Glimepiride • Metformin Hydrochloride • Pioglitazone Hydrochloride • Vildagliptin • Vildagliptin + Metformin Hydrochloride • Gastrointestinal LATIN ORAL EUROPE AMERICA APMA Bifidobacterium Animalis • Esomeprazole Magnesium • Famotidine • Hydrotalcite • Hymecromone • Lactobacillus Acidophilus + Bifidobacterium Animalis • Lactobacillus Acidophilus + Bifidobacterium Infantis + Enterococcus Faecium • • Lansoprazole • Loperamide Hydrochloride • Omeprazole • • Pantoprazole Sodium • Rabeprazole Sodium • Saccharomyces Boulardii • STERILE Omeprazole Sodium • Pantoprazole Sodium • Hormones LATIN ORAL EUROPE AMERICA APMA Cinacalcet Hydrochloride • Levothyroxine Sodium • STERILE Octreotide Acetate • The availability of some of the listed products may be limited by geographical territory. 7 Immunosuppressants LATIN ORAL EUROPE AMERICA APMA Ciclosporin • • Desloratadine • • Loratadine • Mycophenolate Mofetil • • Mycophenolate Sodium • Tacrolimus • Men's Health LATIN ORAL EUROPE AMERICA APMA Sildenafil Citrate • • • Silodosin • Tadalafil • • • Musculoskeletal LATIN ORAL EUROPE AMERICA APMA Allopurinol • • STERILE Zoledronic Acid • 8 The availability of some of the listed products may be limited by geographical territory. Oncology LATIN ORAL EUROPE AMERICA APMA Anastrozole • • Bicalutamide • Lenalidomide • Tamoxifen Citrate • STERILE 5-Fluorouracil • • • Arsenic Trioxide • Calcium Folinate • • Carboplatin • • • Cisplatin • • • Cytarabine • Docetaxel • • • Doxorubicin Hydrochloride • • • Epirubicin Hydrochloride • • • Etoposide • • • Fludarabine Phosphate • • • Fulvestrant • • • Gemcitabine Hydrochloride • • • Idarubicin Hydrochloride • • • Irinotecan Hydrochloride • Methotrexate Disodium • • • Mitoxantrone Hydrochloride • • • Oxaliplatin • • • Paclitaxel • • • Pemetrexed • Pemetrexed Disodium • • Rituximab • Topotecan Hydrochloride • Vinorelbine Ditartrate • • • Ophtha LATIN OPHTHALMIC EUROPE AMERICA APMA Latanoprost • Latanoprost + Timolol Maleate • Travoprost + Timolol Maleate • The availability of some of the listed products may be limited by geographical territory. 9 Others LATIN STERILE EUROPE AMERICA APMA Granisetron Hydrochloride • Ondansetron Hydrochloride • Pain LATIN OPHTHALMIC EUROPE AMERICA APMA Paracetamol • ORAL Buprenorphine Hydrochloride • Celecoxib • Etoricoxib • Ibuprofen • • Ibuprofen Lysinate • Ketoprofen Lysine Salt • Naproxen Sodium • Oxycodone Hydrochloride • Oxycodone Hydrochloride + Naloxone Hydrochloride • Paracetamol • • Paracetamol + Caffeine + Codeine Phosphate • Sumatriptan Succinate • Tilidine Hydrochloride + Naloxone Hydrochloride • Tramadol Hydrochloride + Paracetamol • Zolmitriptan • OTHER Paracetamol • PATCH Buprenorphine • STERILE Tramadol Hydrochloride • 10 The availability of some of the listed products may be limited by geographical territory. Respiratory LATIN INHALATION EUROPE AMERICA APMA Budesonide • Budesonide + Formoterol Fumarate • • Salbutamol Sulfate • • • Salmeterol Xinafoate + Fluticasone Propionate • • • NASAL Budesonide • • • Mometasone Furoate • • • ORAL Fenspiride Hydrochloride • Montelukast Sodium • • Salbutamol Sulfate • Theophylline • Urology LATIN ORAL EUROPE AMERICA APMA Solifenacin Succinate • • VMS LATIN ORAL EUROPE AMERICA APMA Potassium Chloride • The availability of some of the listed products may be limited by geographical territory. 11 Women's Health LATIN ORAL EUROPE AMERICA APMA Alendronate Sodium Trihydrate • Alendronate Sodium Trihydrate + Colecalciferol • • Colecalciferol • Desogestrel • • • Desogestrel + Ethinylestradiol • • • Drospirenone + Ethinylestradiol • • Estradiol • Estradiol Valerate + Dienogest • Estradiol + Norethisterone Acetate • Ethinylestradiol + Gestodene • Levonorgestrel • Metronidazole • Ornidazole • Risedronate Sodium • Ritodrine Hydrochloride • Secnidazole • PATCH Estradiol • • STERILE Calcium Gluconate + Calcium Lactobionate • OTHER FINISHED DOSAGE FORMS ARE AVAILABLE ON REQUEST. If you would like to discuss B2B opportunities, or if you do not see the product you are searching for, please get in touch via the following routes: Finished Dosage Forms Email: [email protected] 12 The availability of some of the listed products may be limited by geographical territory. Active Pharmaceutical Ingredients Anti-Infectives ORAL USAGE Amoxicillin Trihydrate + Potassium Clavulanate 2:1 For tablets Amoxicillin Trihydrate + Potassium Clavulanate 4:1 For tablets & suspensions Amoxicillin Trihydrate + Potassium Clavulanate 7:1 For tablets & suspensions Amoxicillin Trihydrate For Direct Compression For tablets Amoxicillin Trihydrate For Direct Compression II For dispersible tablets Amoxicillin Trihydrate microfine For oral solutions Amoxicillin Trihydrate powder + compacted For oral preparations Ampicillin Anhydrous powder For oral preparations Ampicillin Trihydrate powder + compacted For oral preparations Cloxacillin Sodium powder + compacted For oral preparations Dicloxacillin Sodium powder + compacted For oral preparations
Load more

Recommended publications
  • Photoaging & Skin Damage
    Use_for_Revised_OFC_Only_2006_PhotoagingSkinDamage 5/21/13 9:11 AM Page 2 PEORIA (309) 674-7546 MORTON (309) 263-7546 GALESBURG (309) 344-5777 PERU (815) 224-7400 NORMAL (309) 268-9980 CLINTON, IA (563) 242-3571 DAVENPORT, IA (563) 344-7546 SoderstromSkinInstitute.comsoderstromskininstitute.com FROMFrom YOUR Your DERMATOLOGISTDermatologist [email protected]@skinnews.com PHOTOAGING & SKIN DAMAGE Before You Worship The Sun Who’s At Risk? Today, many researchers and dermatologists Skin types that burn easily and tan rarely are believe that wrinkling and aging changes of the skin much more susceptible to the ravages of the sun on the are much more related to sun damage than to age! skin than are those that tan easily, rather than burn. Many of the signs of skin damage from the sun are Light complected, blue-eyed, red-haired people such as pictured on these pages. The decrease in the ozone Swedish, Irish, and English, are usually more suscep- layer, increasing the sun’s intensity, and the increasing tible to photo damage, and their skin shows the signs sun exposure among our population – through work, of photo damage earlier in life and in a more pro- sports, sunbathing and tanning parlors – have taken a nounced manner. Dark complexions give more protec- tremendous toll on our skin. Sun damage to the skin tion from light and the sun. ranks with other serious health dangers of smoking, alcohol, and increased cholesterol, and is being seen in younger and younger people. NO TAN IS A SAFE TAN! Table of Contents Sun Damage .............................................Pg. 1 Skin Cancer..........................................Pgs. 2-3 Mohs Micrographic Surgery ......................Pg.
    [Show full text]
  • Zhejiang Xianju Pharmaceutical Co. Ltd
    No.1, Xianyao Road, Xianju, Zhejiang, China, 317300 Xianju Pharma Outline Outline I. Brief Introduction II. Quality Unit III. Production System IV. EHS System I. Brief Introduction Xianju Pharma Zhejiang Xianju Pharmaceutical Co., Ltd. A professional manufacturer of steroids and hormone products with largest scale and maximum varieties in China. A state-designated manufacturer of contraceptive drugs in China. Company Milestones Jan 1972 Foundation of company May 1997 Incorporated into Zhejiang Medicine Co., Ltd Oct. 1999 Listed in Shanghai Stock Market Jun. 2000 Reorganized into Xianju Pharmaceutical Co., Ltd Dec. 2001 Reformed to Zhejiang Xianju Pharmaceutical Co., Ltd Jan. 2010 listed in Shenzhen Stock Market Location of Xianju There are six airports around Shanghai Xianju, which makes us easily accessible for our partners. Headquarter Hangzhou Located in Xianju, Taizhou City Ningbo Yangfu Site (FPPs) Located in Yangfu, Xianju, Taizhou Yiwu City 6.8km from headquarter Duqiao Site (APIs) Located in LinHai, TaiZhou City, 82.9km from headquarter Taizhou Wenzhou Yangfu Site (APIs) Under construction, finish at 2017 Company Organization General Manager Vice G.M for Vice G.M Vice G.M for Vice G.M for Vice G.M for Quality Director Sales for Market Administration Finance Technology Finance Dept Finance Dept Application Tech Dept Endineering Construction Domestic DrugRegistrationDept. Research& Development Dept. Marketing Dept. Marketing Quality Control Quality Domestic Trading Dept International TradeDep Quality Assurance For FPP Quality Assurance For API Regulatory AffairsDept Human Resource Dept Information Technology Dept Dept Enterprise Management Dept Affairs Administrative Taizhou Xianju Quality System Quality Xianju Taizhou . t G.M. Assistant EHS Dept Production Management Dept G.M.
    [Show full text]
  • Pemetrexed-Lilly-Epar-Product-Information En.Pdf
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Pemetrexed Lilly 100 mg powder for concentrate for solution for infusion Pemetrexed Lilly 500 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pemetrexed Lilly 100 mg powder for concentrate for solution for infusion Each vial contains 100 mg of pemetrexed (as pemetrexed disodium). Excipient with known effect Each vial contains approximately 11 mg sodium. Pemetrexed Lilly 500 mg powder for concentrate for solution for infusion Each vial contains 500 mg of pemetrexed (as pemetrexed disodium). Excipient with known effect Each vial contains approximately 54 mg sodium. After reconstitution (see section 6.6), each vial contains 25 mg/mL of pemetrexed. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. White to either light yellow or green-yellow lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Malignant pleural mesothelioma Pemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1). Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Symptom Management in the Last Days of Life This Is About Managing Symptoms in the Last Days of Life Where the Dying Process Has Set In
    Symptom management in the last days of life This is about managing symptoms in the last days of life where the dying process has set in. It assumes that the therapeutic aims are therefore: To allow the patient to die comfortably To support the family/carers and to start to prepare them for bereavement To discontinue any burdensome or irrelevant clinical procedures Key Prescribing Questions in the last days of life 1. Ahead of time Page a. Pre-emptive prescribing 1 b. Differences in specific circumstances 1 2. Once the oral route is lost a. What can be stopped? – managing co-morbidities at the end of life 2 (insulin; anti-epileptics; steroids; cardiac medicines) b. How to prescribe a syringe pump 3 i. Opioid conversion 4 ii. Combining drugs in a syringe – what can and can’t be mixed? 5 iii. Dosing other drugs 6 c. What can and can’t be given subcutaneously 7 3. Problems a. Uncontrolled symptoms (pain; restlessness; secretions; breathlessness; nausea; thirst) 8 b. Obtaining medicines out of hours 11 c. References and contact phone numbers 12 Pre-emptive prescribing The pre-emptive prescribing of p.r.n. medication for anticipated symptoms can avoid great distress. The cost is negligible and it saves time on the part of both families and out-of-hours health professionals. Typical maximum doses are described on page 22, but the doses needed by individuals vary widely: it is more important to assess the effectiveness of each p.r.n. before repeating or increasing doses – if a p.r.n. is ineffective, try a different approach or seek advice (see flow diagrams) A typical “pre-emptive p.r.n.” regimen for patients approaching the end of life might include: Morphine sulphate 2.5-5mg 1-4 hourly p.r.n.
    [Show full text]
  • Pemetrexed (Alimta) Is Covered Pemetrexed (Alimta®) Is Considered Medically Necessary for the Treatment of Patients With
    Corporate Medical Policy ® Pemetrexed (Alimta ) File Name: pemetrexed_alimta Origination: 8/2016 Last CAP Review: 4/2020 Next CAP Review: 4/2021 Last Review: 4/2020 Description of Procedure or Service ® Pemetrexed (Alimta ) is a folate analog metabolic inhibitor indicated for non-squamous non-small cell lung cancer, mesothelioma, urothelial carcinoma, epithelial ovarian cancer and thymic carcinoma. Alimta is indicated in combination with cisplatin therapy for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer, and in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic non- squamous non-small cell lung cancer and with no EGFR or ALK genomic tumor aberrations. Alimta is indicated for the maintenance treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first- line chemotherapy. Alimta is indicated as a single agent for the treatment of patients with recurrent, metastatic non- squamous non-small cell lung cancer after prior chemotherapy. Alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy ® BCBSNC will provide coverage for Pemetrexed (Alimta ) when it is determined to be medically necessary because the medical criteria and guidelines noted below are met. Benefits Application This medical policy relates only to the services or supplies described herein.
    [Show full text]
  • Original Article Pemetrexed and Cyclophosphamide Combination Therapy for the Treatment of Non-Small Cell Lung Cancer
    Int J Clin Exp Pathol 2015;8(11):14693-14700 www.ijcep.com /ISSN:1936-2625/IJCEP0012945 Original Article Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer Dong Li1, Song He2 1Department of Cardiothoracic Surgery, Central Hospital of Zibo, Zibo 250012, Shandong, China; 2Maanshan Center for Clinical Laboratory, Maanshan Municipal Hospital Group, Maanshan, Anhui, China Received July 15, 2015; Accepted October 13, 2015; Epub November 1, 2015; Published November 15, 2015 Abstract: Lung cancer is the leading cause of cancer-related mortality. This study was undertaken to investigate the efficacy and safety of adding regulatory T cell inhibitor cyclophosphamide to pemetrexed therapy for the second-line treatment of NSCLC with wild-type epidermal growth factor receptor (EGFR). A total of 70 patients were screened between March 2011 and December 2013, out of which 62 patients were enrolled in the study. Patients were randomized to receive 500 mg/m2 pemetrexed in combination with 20 mg/kg cyclophosphamide in a 21 day cycle (n=30) or 500 mg/m2 pemetrexed (n=32), and followed up for 30 months. Disease progression was observed in 23 patients in the pemetrexed plus cyclophosphamide arm and 27 patients in the pemetrexed monotherapy arm. Median progression-free survival was 3.6 months (95% confidence interval [CI], 1.3 to 5.9 months) in the peme- trexed plus cyclophosphamide arm and 2.2 months (95% CI, 1.3 to 3.1 months) in the pemetrexed monotherapy arm. The 6-month PFS rates were 22% (95% CI, 10 to 34) and 14.5% (95% CI, 6 to 23) in the pemetrexed plus cyclophosphamide arm and pemetrexed monotherapy arm, respectively.
    [Show full text]
  • Acetadote (Acetylcysteine) Injection Is Available As a 20% Solution in 30 Ml (200Mg/Ml) Single Dose Glass Vials
    NDA 21-539/S-004 Page 3 Acetadote® (acetylcysteine) Injection Package Insert NDA 21-539/S-004 Page 4 RX ONLY PRESCRIBING INFORMATION ACETADOTE® (acetylcysteine) Injection For Intravenous Use DESCRIPTION Acetylcysteine injection is an intravenous (I.V.) medication for the treatment of acetaminophen overdose. Acetylcysteine is the nonproprietary name for the N-acetyl derivative of the naturally occurring amino acid, L-cysteine (N-acetyl-L-cysteine, NAC). The compound is a white crystalline powder, which melts in the range of 104° to 110°C and has a very slight odor. The molecular formula of the compound is C5H9NO3S, and its molecular weight is 163.2. Acetylcysteine has the following structural formula: H CH3 N SH O COOH Acetadote is supplied as a sterile solution in vials containing 20% w/v (200 mg/mL) acetylcysteine. The pH of the solution ranges from 6.0 to 7.5. Acetadote contains the following inactive ingredients: 0.5 mg/mL disodium edetate, sodium hydroxide (used for pH adjustment), and Sterile Water for Injection, USP. CLINICAL PHARMACOLOGY Acetaminophen Overdose: Acetaminophen is absorbed from the upper gastrointestinal tract with peak plasma levels occurring between 30 and 60 minutes after therapeutic doses and usually within 4 hours following an overdose. It is extensively metabolized in the liver to form principally the sulfate and glucoronide conjugates which are excreted in the urine. A small fraction of an ingested dose is metabolized in the liver by isozyme CYP2E1 of the cytochrome P-450 mixed function oxidase enzyme system to form a reactive, potentially toxic, intermediate metabolite. The toxic metabolite preferentially conjugates with hepatic glutathione to form nontoxic cysteine and mercapturic acid derivatives, which are then excreted by the kidney.
    [Show full text]
  • Late Stent Thrombosis After Paclitaxel-Eluting Stent Placement in a Patient with Essential Thrombocytosis
    558 Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2010;38(8):558-560 Late stent thrombosis after paclitaxel-eluting stent placement in a patient with essential thrombocytosis Esansiyel trombositozlu bir hastada paklitaksel salınımlı stent yerleştirme sonrası gelişen geç stent trombozu Telat Keleş, M.D., Nihal Akar Bayram, M.D., Tahir Durmaz, M.D., Engin Bozkurt, M.D. Department of Cardiology, Ankara Atatürk Education and Research Hospital, Ankara We report on a case of late stent thrombosis after drug- Bu yazıda, esansiyel trombositozlu bir hastada ilaç sa- eluting stent placement in a patient with essential throm- lınımlı stent yerleştirme sonrası gelişen geç stent trom- bocytosis. A 51-year-old male patient with a three-month bozu sunuldu. Üç ay önce sol ön inen artere paklitak- history of paclitaxel-eluting stent placement to the left sel salınımlı stent yerleştirilen 51 yaşındaki erkek hasta anterior descending artery presented with a complaint şiddetli retrosternal göğüs ağrısı yakınmasıyla başvur- of severe retrosternal chest pain. A high platelet count du. İki ay öncesinde hastanın trombosit sayımı yüksek (1,063,000/mm3) was detected two months prior to (1063000/mm3) bulunmuş ve durumu esansiyel trombo- presentation, which was interpreted as essential throm- sitoz olarak yorumlanmıştı. Hasta standart ikili antitrom- bocytosis. He was on standard dual antiplatelet therapy bosit tedavi (aspirin ve klopidogrel) görmekteydi. Elekt- (aspirin and clopidogrel). The electrocardiogram showed rokardiyografide V1-V6 derivasyonlarında ST-segment ST-segment elevation in leads V1-V6. Emergent coro- yükselmesi izlendi. Acil koroner anjiyografide paklitaksel nary angiography revealed thrombotic total occlusion salınımlı stent yerinde trombotik tam tıkanıklık gözlendi. at the location of the paclitaxel-eluting stent.
    [Show full text]
  • The Promise of N-Acetylcysteine in Neuropsychiatry
    Review The promise of N-acetylcysteine in neuropsychiatry 1,2,3,4 5,6 1 1,2,4 Michael Berk , Gin S. Malhi , Laura J. Gray , and Olivia M. Dean 1 School of Medicine, Deakin University, Geelong, Victoria, Australia 2 Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia 3 Orygen Research Centre, Parkville, Victoria, Australia 4 The Florey Institute of Neuroscience and Mental Health, Victoria, Australia 5 Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia 6 CADE Clinic, Department of Psychiatry, Level 5 Building 36, Royal North Shore Hospital, St Leonards, 2065, Australia N-Acetylcysteine (NAC) targets a diverse array of factors with the pathophysiology of a diverse range of neuropsy- germane to the pathophysiology of multiple neuropsy- chiatric disorders, including autism, addiction, depression, chiatric disorders including glutamatergic transmission, schizophrenia, bipolar disorder, and Alzheimer’s and Par- the antioxidant glutathione, neurotrophins, apoptosis, kinson’s diseases [3]. Determining precisely how NAC mitochondrial function, and inflammatory pathways. works is crucial both to understanding the core biology This review summarises the areas where the mecha- of these illnesses, and to opening the door to other adjunc- nisms of action of NAC overlap with known pathophysi- tive therapies operating on these pathways. The current ological elements, and offers a pre´ cis of current literature article will initially review the possible mechanisms of regarding the use of NAC in disorders including cocaine, action of NAC, and then critically appraise the evidence cannabis, and smoking addictions, Alzheimer’s and Par- that suggests it has efficacy in the treatment of neuropsy- kinson’s diseases, autism, compulsive and grooming chiatric disorders.
    [Show full text]
  • Future Directions for Intrathecal Pain Management 93
    NEUROMODULATION: TECHNOLOGY AT THE NEURAL INTERFACE Volume 11 • Number 2 • 2008 http://www.blackwell-synergy.com/loi/ner ORIGINAL ARTICLE FBlackwell uturePublishing Inc Directions for Intrathecal Pain Management: A Review and Update From the Interdisciplinary Polyanalgesic Consensus Conference 2007 Timothy Deer, MD* • Elliot S. Krames, MD† • Samuel Hassenbusch, MD, PhD‡ • Allen Burton, MD§ • David Caraway, MD¶ • Stuart Dupen, MD** • James Eisenach, MD†† • Michael Erdek, MD‡‡ • Eric Grigsby, MD§§ • Phillip Kim, MD¶¶ • Robert Levy, MD, PhD*** • Gladstone McDowell, MD††† • Nagy Mekhail, MD‡‡‡ • Sunil Panchal, MD§§§ • Joshua Prager, MD¶¶¶ • Richard Rauck, MD**** • Michael Saulino, MD†††† •Todd Sitzman, MD‡‡‡‡ • Peter Staats, MD§§§§ • Michael Stanton-Hicks, MD¶¶¶¶ • Lisa Stearns, MD***** • K. Dean Willis, MD††††† • William Witt, MD‡‡‡‡‡ • Kenneth Follett, MD, PhD§§§§§ • Mark Huntoon, MD¶¶¶¶¶ • Leong Liem, MD****** • James Rathmell, MD†††††† • Mark Wallace, MD‡‡‡‡‡‡ • Eric Buchser, MD§§§§§§ • Michael Cousins, MD¶¶¶¶¶¶ • Ann Ver Donck, MD******* *Charleston, WV; †San Francisco, CA; ‡Houston, TX; §Houston, TX; ¶Huntington, WV; **Bellevue, WA; ††Winston Salem, NC; ‡‡Baltimore, MD; §§Napa, CA; ¶¶Wilmington, DE; ***Chicago, IL; †††Columbus, OH; ‡‡‡Cleveland, OH; §§§Tampa, FL; ¶¶¶Los Angeles, CA; ****Winston Salem, NC; ††††Elkings Park, PA; ‡‡‡‡Hattiesburg, MS; §§§§Colts Neck, NJ; ¶¶¶¶Cleveland, OH; *****Scottsdale, AZ; †††††Huntsville, AL; ‡‡‡‡‡Lexington, KY; §§§§§Iowa City, IA; ¶¶¶¶¶Rochester, NY; ******Nieuwegein, The Netherlands; ††††††Boston, MA; ‡‡‡‡‡‡La Jolla, CA; §§§§§§Switzerland; ¶¶¶¶¶¶Australia; and *******Brugge, Belgium ABSTRACT Background. Expert panels of physicians and nonphysicians, all expert in intrathecal (IT) therapies, convened in the years 2000 and 2003 to make recommendations for the rational use of IT analgesics, based on the preclinical and clinical literature known up to those times, presentations of the expert panels, discussions on current practice and standards, and the result of surveys of physicians using IT agents.
    [Show full text]
  • A Preclinical Evaluation of Pemetrexed and Irinotecan Combination As Second-Line Chemotherapy in Pancreatic Cancer
    British Journal of Cancer (2007) 96, 1358 – 1367 & 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00 www.bjcancer.com A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer A Mercalli1, V Sordi1, R Formicola1, M Dandrea2, S Beghelli2, A Scarpa2, V Di Carlo1, M Reni3,4 and L Piemonti*,1,4 1 2 Laboratory of Experimental Surgery, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy; Section of Anatomic Pathology, Department 3 of Pathology, University of Verona, Strada Le Grazie 8, Verona 37134, Italy; Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy Translational Therapeutics Gemcitabine (GEM)-based chemotherapy is regarded as the standard treatment of pancreatic adenocarcinoma, but yields a very limited disease control. Very few studies have investigated salvage chemotherapy after failure of GEM or GEM-containing chemotherapy and preclinical studies attempting to widen the therapeutic armamentarium, not including GEM, are warranted. MIA PaCa2, CFPAC-1 and Capan-1 pancreatic cancer cell lines were treated with GEM, fluouracil (5-FU), docetaxel (DCT), oxaliplatin (OXP), irinotecan (CPT-11), pemetrexed (PMX) and raltitrexed (RTX) as single agent. Pemetrexed, inducing apoptosis with IC50s under the Cmax in the three lines tested, appeared the most effective drug as single agent. Based on these results, schedule- and concentration-dependent drug interactions (assessed using the combination index) of PMX/GEM, PMX/DCT and PMX–CPT-11 were evaluated. The combinatory study clearly indicated the PMX and CPT-11 combination as the most active against pancreatic cancer. To confirm the efficacy of PMX–CPT-11 combination, we extended the study to a panel of 10 pancreatic cancer cell lines using clinically relevant concentrations (PMX 10 mM; CPT-11 1 mm).
    [Show full text]